Workflow
尔康制药9月9日获融资买入1107.96万元,融资余额2.64亿元

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Erkang Pharmaceutical, indicating a decline in stock price and significant financing activities [1] - On September 9, Erkang Pharmaceutical's stock fell by 2.07%, with a trading volume of 157 million yuan, and a net financing purchase of 1.9125 million yuan [1] - As of September 9, the total balance of margin trading for Erkang Pharmaceutical was 264 million yuan, accounting for 3.37% of its market capitalization, which is at a high level compared to the past year [1] Group 2 - As of June 30, the number of shareholders for Erkang Pharmaceutical increased to 42,700, a rise of 4.40%, while the average circulating shares per person decreased by 4.22% to 33,275 shares [2] - For the first half of 2025, Erkang Pharmaceutical reported a revenue of 682 million yuan, representing a year-on-year growth of 9.74%, and a net profit attributable to shareholders of 37.6346 million yuan, which is a significant increase of 497.36% [2] Group 3 - Since its A-share listing, Erkang Pharmaceutical has distributed a total of 540 million yuan in dividends, with 61.8781 million yuan distributed over the past three years [3] - As of June 30, 2025, Hong Kong Central Clearing Limited was the sixth largest circulating shareholder of Erkang Pharmaceutical, holding 21.5598 million shares, an increase of 6.4651 million shares from the previous period [3]